Latest From Century Therapeutics
Investment from Janssen helps to validate the platform developed by the San Diego-based company.
Previewing the year to come, our journalists contacted more than 80 industry executives and experts for their views on what 2020 could hold for the biopharma sector. A series of articles based on these discussions were published by In Vivo’s sister publication Scrip. The following are highlights of the key issues that are top of mind for industry leaders this year, including digital tools, advanced therapies, the US election and manufacturing.
Advances in multiple scientific areas will mature into novel therapeutics, often tailored for the individual patient and increasingly curative, making biopharma an exciting place to be in 2020.
Bayer’s ambitious campaign to reposition itself as a global leader in two complementary fields – health and nutrition – will face its toughest test in the US, with its highly litigious approach to product liability and a tendency to target pharmaceuticals as the source of the health system’s affordability and access problems.
- Gene Therapy, Cell Therapy
- Therapeutic Areas
- North America
- Company Type
- Parent & Subsidiaries
- Century Therapeutics
- Senior Management
Lalo Flores, PhD, CEO
Hy Levitsky, MD, Pres., R&D
Luis Borges, PhD, CSO
Adrienne Farid, PhD, Chief Dev. Officer
Douglas Carr, VP, Fin. & Operations
- Contact Info
3675 Market St.
Philadelphia, PA 19104